| Net income (loss) | -1.34M |
| Depreciation | 448K |
| Amortization | 539K |
| Stock based compensation expense | 52K |
| Change in fair value of warrant liability | |
| Accounts receivable - net | 1.27M |
| Inventories | -238K |
| Prepaid expenses and other assets | -303K |
| Accounts payable and accrued expenses | -1.51M |
| Net cash provided by (used in) operating activities | -1.2M |
| Capital expenditures | -198K |
| Patent expenditures | -275K |
| Net cash used in investing activities | -348K |
| Payments on bank term loan | -223K |
| Payments on MEDC/MSF term loan | 0 |
| Payments on related parties debt | |
| Proceeds from exercise of restricted shares | |
| Proceeds from exercise of stock options | |
| Net cash used in financing activities | 1.54M |
| Net decrease in cash and cash equivalents | -10K |
| Cash and cash equivalents at beginning of period | 120K |
| Cash and cash equivalents at end of period | 110K |
| Cash paid for income taxes | |
| Cash paid for interest | 222K |
| Conversion of accrued MEDC loan interest to common stock | |